GeoVax, Inc.

GeoVax (Nasdaq: $GOVX) is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumor cancers.

[GeoVax, Inc. @Geovax_News]

Taking the stage today at World Vaccine Congress Europe 2026: Senthil Ranganathan, PhD, will present “Revolutionizing MVA – Single Dose and Continuous Cell-Line Manufacturing” at 11:00 a.m. at RAI Amsterdam. $GOVX

[GeoVax, Inc. @Geovax_News]

Stockpiles are only useful when supply can be replenished. Long-term orthopox planning increasingly includes manufacturing capacity, procurement pathways and additional vaccine sources. https://t.co/A3BXzPCphA $GOVX

[GeoVax, Inc. @Geovax_News]

Next week, GeoVax heads to Amsterdam for #WVCEU, where Senthil Ranganathan, PhD, will highlight advances in next-generation MVA technology focused on single-dose vaccination and continuous cell-line manufacturing.

Presentation details: https://t.co/JZMMw7HMNT $GOVX

[GeoVax, Inc. @Geovax_News]

Regulatory strategy can shape clinical development from the start. GEO-MVA is advancing under an EMA-aligned immunobridging pathway designed to compare its immune response with an approved MVA comparator. https://t.co/A3BXzPCphA $GOVX

[GeoVax, Inc. @Geovax_News]

Recent advances in immuno-oncology are highlighting the role of tumor priming alongside checkpoint blockade.

GeoVax CEO David Dodd and CMO Kelly McKee Jr., MD, MPH examine the clinical evidence and Gedeptin® research in a new @OncoZine op-ed.

https://t.co/V0EwWaryTh $GOVX

[GeoVax, Inc. @Geovax_News]

MVA technology has a long history in orthopox vaccination. GeoVax is applying MVA expertise to develop GEO-MVA for mpox and smallpox while advancing the program toward pivotal clinical evaluation. https://t.co/A3BXzPCphA $GOVX

[GeoVax, Inc. @Geovax_News]

A resilient orthopox vaccine market needs more than demand forecasting. Additional MVA manufacturing capacity can give governments more options for future procurement, stockpiling and outbreak response. https://t.co/A3BXzPCphA $GOVX

[GeoVax, Inc. @Geovax_News]

Today, GeoVax announced Dr. Senthil Ranganathan will present on single-dose MVA vaccine research and manufacturing advances at World Vaccine Congress Europe 2026 on October 19, 2026, in Amsterdam.

Read the release for details: https://t.co/ToR3kHDpe4 $GOVX @vaccinenation #WVCEU

[GeoVax, Inc. @Geovax_News]

GeoVax’s AGE1® continuous avian cell-line platform is being developed to support scalable MVA production. Increasing manufacturing capacity can help expand supply as demand for orthopox vaccines evolves. https://t.co/A3BXzPCphA $GOVX

[GeoVax, Inc. @Geovax_News]

Since August, an increasing proportion of U.S. Clade I mpox cases have occurred without recent international travel or known links to travelers. @CDCgov says this indicates a likely transition to sustained Clade Ib transmission.

Read more: https://t.co/3EEZk3Ollp $GOVX

[GeoVax, Inc. @Geovax_News]

GEO-MVA has advanced through manufacturing, regulatory, clinical and preclinical milestones ahead of its planned pivotal study. The program now has released GMP clinical product and trial infrastructure moving into place. https://t.co/A3BXzPCphA $GOVX

[GeoVax, Inc. @Geovax_News]

Today, GeoVax highlighted a new CDC assessment indicating a likely transition to sustained Clade Ib mpox transmission in the U.S., with presumed domestic transmission reported across more than 10 jurisdictions.

Read more: https://t.co/TRtLC3zFYd $GOVX

[GeoVax, Inc. @Geovax_News]

GeoVax is bringing multiple workstreams together around GEO-MVA: manufacturing, regulatory planning, clinical operations and procurement discussions. The next stage is about translating that foundation into clinical execution. https://t.co/A3BXzPCphA $GOVX

[GeoVax, Inc. @Geovax_News]

Clinical execution is taking shape for GEO-MVA. GeoVax has selected the CRO and European sites planned for the pivotal immunobridging study, with recruitment flexibility built into the program.

Learn more: https://t.co/A3BXzPCphA $GOVX

[GeoVax, Inc. @Geovax_News]

MVA-X showed complete protection against lethal and high-dose orthopoxvirus challenge at Days 55, 90 and 150 following a single vaccination in preclinical studies, along with durable antigen-specific CD8+ T-cell responses.

ICYMI, read the release: https://t.co/bNTaLX6mXe $GOVX

[GeoVax, Inc. @Geovax_News]

Mpox vaccine access is taking a longer-term shape. A new global stockpile is designed to support timely, equitable access during future outbreaks, reinforcing the role of sustainable supply alongside emergency response. https://t.co/A3BXzPCphA $GOVX

[GeoVax, Inc. @Geovax_News]

Measles has returned to levels that challenge the meaning of U.S. elimination status. GeoVax CEO David Dodd spoke with @CityAndStatePA about Pennsylvania’s outbreak, declining vaccination rates and the broader implications for public health.

Read: https://t.co/5nFy9rIu7T $GOVX

[GeoVax, Inc. @Geovax_News]

Today, GeoVax announced preclinical research showing durable single-dose protection with MVA-X, including protection against lethal challenge with highly pathogenic Clade I mpox virus.

Read more: https://t.co/bNTaLX6mXe $GOVX

[GeoVax, Inc. @Geovax_News]

GeoVax’s agreement with CEPI brings independent, standardized laboratory testing into the planned GEO-MVA Phase 3 study, supporting clinical development and future regulatory interactions.

Read more: https://t.co/RQOA3xnf2h $GOVX

[GeoVax, Inc. @Geovax_News]

AI is bringing renewed attention to bacteriophage technology, a field David Dodd has worked with since the 1980s. In @MyBioTechniques, GeoVax’s CEO discusses the potential of applying new tools to an older technology.

Read: https://t.co/L3uDs9a0m7 $GOVX